Objective: To compare and evaluate the impact of inhaled versus injected insulin on potential mediators of patient acceptance of insulin therapy while maintaining comparable HbA 1c levels. Research Design and Methods: During a non-inferiority efficacy trial conducted in 40 centers in the United States, we surveyed treatment satisfaction, quality of life and adherence barriers at weeks -4, -1, 6, 12, 20 and 24 in adolescents aged 12-17 yrs and adults with type 1 diabetes who received premeal regular plus twice daily NPH insulin during a 4-week run-in, and then were randomized to premeal inhaled human insulin plus twice daily NPH (adults, N=102; adolescents, N=60) (INH) or remaining on run-in therapy (N=105 and 60) (SC). Results: Overall treatment satisfaction (0-100) increased by 13.2±1.1 units for INH (baseline = 63.3±1.2) compared to 1.7±0.8 for SC (baseline = 64.1±1.2), P<0.0001. All 12 satisfaction subscales favored INH (all P<0.01) and effects did not vary by age or sex. Despite similar baseline-adjusted endpoint HbA 1c for INH (7.7±0.1%) and SC (7.9±0.1%), quality-of-life scales of mental health, symptoms, health status, cognitive functioning and adherence barriers during treatment were more favorable for INH (all P<0.05). Greater satisfaction was associated with fewer barriers to insulin adherence (rho = -0.78, P<0.0001) and a greater reduction in HbA 1c (rho = -0.18, P<0.001).
INTRODUCTION
Maintaining HbA 1c levels less than 7% in persons with type 1 diabetes has been shown to reduce microvascular and some macrovascular complications (1, 2) . Reaching HbA 1c goals by intensifying the insulin regimen often requires either an insulin pump or a basal/bolus multiple injection insulin regimen. However, use of the pump has been limited by its cost, required technical expertise and the relative paucity of health care providers trained in its use, and the acceptance of basal/bolus insulin regimens is hindered by the burden of multiple injections (3 -6) .
Clinical trials have demonstrated that inhaled insulin is comparable to injected insulin in lowering HbA 1c in persons with type 1 (7, 8) and type 2 diabetes (9) . However, the clinical rationale for its use is based upon the belief that multiple inhalations will be more acceptable to patients, thereby promoting increased adherence to intensive insulin regimens. However, evidence of this causal relationship has not been established empirically during clinical trials of efficacy since adherence to treatment and HbA 1c goals are strictly enforced for all patients. Additionally, real world clinical experience with the only form of inhaled insulin approved by the FDA is lacking since it has just recently become available.
While empirical data documenting the relationship between greater acceptance and superior glycemic control is not available, mediators in the pathway --namely, treatment satisfaction, quality of life and barriers to insulin adherence --can be evaluated. Such measures could provide valuable insight when weighing the risks and benefits of incorporating inhaled insulin delivery as part of intensive insulin regimens. The purpose of our study was to compare the impact of inhaled versus injected insulin on potential mediators of adherence during a clinical trial (8) which previously reported that inhaled human insulin has comparable safety and efficacy to injected insulin in type 1 diabetes patients currently using multiple daily injections.
METHODS

Study Design:
A detailed description of the clinical results of the parent protocol was published previously (8) .
Briefly, this open-label, randomized, multi-center trial consisted of a screening visit, 4-week lead-in and 24-week treatment phase. A total of 419 individuals with type 1 diabetes for at least 1 year were screened at 40 centers in the U.S. and Canada. Inclusion criteria were: age 12-65 years; stable on an insulin regimen of at least two injections daily for 2 months prior to screening; baseline HbA 1c between 6 and 11% inclusive; fasting plasma C-peptide ≤0.2 pmol/ml; and BMI ≤30 kg/m 2 . Exclusion criteria included poorly controlled asthma, recent smoking and significant laboratory abnormalities. The protocol was approved by the institutional review board and informed consent was obtained from all subjects.
To standardize baseline assessments during the 4 weeks prior to randomization, all patients were switched to subcutaneous premeal regular insulin plus twice daily NPH insulin administered in four subcutaneous injections daily (SC regimen). Target glucose ranges were 80-120 mg/dl (4.4-6.7 mmol/l) before meals and 100-140 mg/dl (5.6-7.8 mmol/l) before bedtime. One-hundred and sixty-two persons were randomized to insulin human [rDNA origin] Inhalation Powder (Exubera® developed by Pfizer Inc. and Nektar Therapeutics) and twice daily NPH insulin (INH Regimen), and 165 to continue on their pre-randomization SC regimen. Inhaled insulin was administered as one to two inhalations within 10 minutes of starting each meal. The insulin powder was packaged in foil blisters of 1-and 3-mg doses, which are approximately equivalent to 3 IU and 8 IU of SC insulin, respectively. Insulin doses were adjusted weekly by the investigator to
Statistical Methods:
Treatment satisfaction and quality of life during treatment at Weeks 6, 12, 20 and 24 were evaluated using linear mixed models with fixed (treatment) and baseline covariate effects. In addition, changes from baseline to endpoint (Week 24 or last visit) satisfaction were compared using analysis of covariance (adjusted for baseline). All P-values report nominal significance levels at alpha = 0.05. For reference, a partial Bonferroni's adjustment for type 1 error for multiple endpoints is provided (22) (23) . Correlation analysis (Pearson r and Spearman's rho) and multiple regression were used to examine the relationships between treatment, glycemic control, satisfaction, adherence barriers and quality of life. Data are given as means ± SE unless specified otherwise. (Table 2) [scale range was 0 (greatest dissatisfaction) to 100 (highest satisfaction)]. The one exception was the low score of 35 for the preference scale suggesting patients had a desire to seek new treatments.
RESULTS
Study
Changes in Glycemic Control:
Baseline-adjusted HbA 1c at final visit was 7.7±0.1% for INH and 7.9±0.1% for SC (baseline = 8.0±0.1% for both groups), P=0.066 between treatment-adjusted HbA 1c baseline to endpoint change. Analysis of covariance showed an overall age effect (P=0.002); however, tests of the interactions indicated that the treatment impact on HbA 1c did not vary by age (P=0.59), sex (P=0.92), or age and sex (P=0.94). The 24-week change in FPG for INH was -1.9 mmol/l (-35 mg/dl), whereas the SC group increased by 0.2 mmol/l (+4 mg/dl), for an adjusted treatment group difference of -2.2 mmol/l (-40 mg/dl) [95% CI: -3.2 mmol/l (-58 mg/dl) to -1.2 mmol/l (-22 mg/dl)].
Patient-Reported Outcomes:
Diabetes Treatment Satisfaction: Baseline to endpoint changes across all 12 satisfaction subscales were more favorable for INH (Table 2) . For the seven regimen-related subscales, improvements for INH were substantially greater than for SC. The two outcomes-related subscales, satisfaction with glycemic control and side effects (primarily weight gain and hypoglycemia), also were more favorable for INH. The three "net benefit" measures of preference (desire to seek alternative diabetes treatment), advocacy (would recommend treatment) and general satisfaction confirmed that patients found INH more acceptable after balancing regimen processes and outcomes. For INH, the overall treatment satisfaction scale increased to 75.3±1.1 by week 6 and remained constant at that level until endpoint while SC did not change. Subgroup treatment comparisons by age group and sex are shown in Figure 1 . None of the 2-and 3-way interactions from the analysis of covariance were statistically significant, indicating that differences between INH and SC regimens were comparable across these demographic subgroups.
Quality of Life during Treatment:
Between screening and baseline there was 0.4% decrease in HbA 1c (P<0.001) with a corresponding improvement in Overall QOL (P=0.024) for both groups combined. Overall QOL [absolute scale range of 500 units and operative range of approximately 64 units (17) ] improved at endpoint by 12.2±3.3 for INH and 2.6±3.4 units for SC (P=0.043), representing a 15% difference in the operative range (0.31±0.15 SD responsiveness units). This difference is within the range of values that are likely to be clinically relevant (10, 11, 17, 21) . As shown in Table 3 , treatment differences in the quality-of-life scales were more favorable for INH including symptom distress, symptom interference in daily activities, cognitive functioning and general health.
The more positive mental and emotional health scores were driven primarily by improvements in anxiety and behavioral and emotional control. Both age and sex modified the treatment effect on mental health [treatment interactions with age group (P=0.001), sex (P=0.002), and age group by sex (P<0.0001)]. Adult females showed the largest INH regimen gain in mental health (+10.9 units) in contrast to adult males (-3.6 units), adolescent males (+5.9 units) and adolescent females (+5.4 units).
Adherence Barriers to Insulin Use:
As shown in Table 3 , the INH group scored more favorably on six of the seven questions relating to barriers to insulin adherence, and these effects did not vary by age. There was no difference with regard to selfconsciousness when using insulin away from home. Six questions addressing barriers specific to injectable insulin revealed that INH rated fewer barriers with insulin (regardless of delivery) [total score 74.2±1.4 for INH vs. 67.0±1.6, for SC (higher score reflects fewer/lower barriers), P=0.001]. Answers to the 12 inhaler-device specific insulin questions confirmed positive endorsement for the inhaler device itself with the highest endorsement rating of 94.9±1.0 (on a scale of 0 to 100) for "reduced pain". All ratings were significantly higher than a neutral endorsement score of 50.0 (P<0.0001), and the average total rating was 78.3±1. 4 Table 3 and, except for "easier to adjust dose", all favored INH. Analyses between endpoint overall treatment satisfaction and insulin adherence barriers demonstrated greater satisfaction with lower barriers (rho = -0.78, P<0.0001). HbA 1c and overall treatment satisfaction correlation analysis indicated that better glycemic control was only weakly associated with higher satisfaction (rho = -0.18, P<0.001) since the lack of change in HbA 1c in this non-inferiority design limited the ability to detect an association.
DISCUSSION
For persons with type 1 diabetes treated with two or more daily injections of regular/NPH insulin and moderately satisfied with their current therapy, there is opportunity to improve their experience with insulin therapy. INH patients reported substantial and stable improvement in their satisfaction ratings between weeks 6 and 24 in contrast to no change for those remaining on the run-in SC regimen. These findings are consistent with other recent studies suggesting that ease of use, convenience, social comfort, and flexibility of the treatment process are important issues to both type 1 and type 2 diabetic patients for insulin administration (24) (25) . Our findings also documented that more positive perceptions of glycemic control, side effects, cognitive function and physical and psychological well being accompanied the higher satisfaction ratings for patients on the INH regimen. It is important to note that our comparative findings may not apply to other insulin regimens.
Although inhaled insulin is not approved for individuals aged 17 and younger, our study demonstrates its impact on satisfaction and quality of life in a younger adolescent population with an average age of 14 years. Using age-appropriate instruments, improvements with inhaled insulin were found to be similar to adults among both males and females. In this age group, most patient-reported outcomes studies evaluating intensive insulin regimens have focused on comparing insulin pumps with multiple daily injections. Results have varied depending upon the responsiveness and sensitivity of the patient-reported measures employed and the study design used, but improvement in patient satisfaction and ability to adhere to intensive regimens are typically higher for the pump. Our study used very sensitive measures and a longitudinal design during which patients answered nearly 2,400 questions over six months. As such, we were able to detect improvements in many domains of satisfaction, quality of life and barriers to adherence for the inhaled insulin group. While the stability and durability of the satisfaction scores argues against a novelty effect, we can not rule out that openly positive or negative reactions of the clinic staff to the inhaler device could have impacted patient attitudes.
The reasons for the positive effects of INH on the quality of life outcomes are uncertain; however, it is possible that the rapidly acting premeal inhaled insulin resulted in a more favorable metabolic profile which mediated these improvements. Also, FPG was lower by 40 mg/dl, and the INH group reported "better glycemic control" even though both groups had statistically comparable HbA 1c . HbA 1c might be too insensitive a measure to detect quality-of-life improvements which are important and salient to patients. Indeed, the higher symptom distress reported by SC patients for thirst, general weakness or fatigue, impaired or worsening vision, lethargy, no energy to do things, and tired, feeling weary are associated with hyperglycemia.
One of the most intriguing findings was that out of 53 symptoms, the symptom which was ameliorated most by INH was "feeling overweight".
Although it was previously reported that body weight increased comparably in both groups (8) , the gains were predominantly in the growing adolescents, which masked the treatment differential in adult females who were most distressed by weight gain. Weight gain with insulin is a significant barrier to adhering to insulin regimens, especially in women.
Because of the non-inferiority design of this trial during which adherence was purposely and strictly enforced in both groups, there was little opportunity to observe differences in HbA 1c resulting from differences in adherence. As such, we chose to focus assessment on patient ratings of barriers to insulin adherence such as, "how much difficulty they had taking every dose of insulin as recommended".
It was not surprising that persons who expressed the most difficulty had the lowest overall satisfaction with treatment. Since it has been observed previously that clinical trials substantially underestimate discontinuation with drug therapy and overestimate adherence, and that quality of life may better predict outcomes in actual practice (26-27), we might anticipate that the more favorable satisfaction and quality-of-life outcomes observed for INH might translate into greater acceptance and better adherence with insulin therapy in clinical practice.
The barriers to effective diabetes management are multifactorial, but our study supports the belief that psychological, behavioral, and attitudinal factors play a role in patient satisfaction with insulin therapy. The use of inhaled insulin in type 1 diabetes should proceed with caution since the long term consequences (both positive and negative) will not be known until real world use and experience yields the long-term safety and efficacy data that only post-marketing surveillance can provide. Communication between physicians and patients pertaining to these patient-centered factors, especially in individuals failing to intensify or maintain their insulin regimen, might better inform the clinical decision process when weighing risks and benefits of alternative methods of delivering intensive insulin regimens. Note: All scales range from 0 -100, and higher scores reflect better or more favorable satisfaction 1. N is less than total due to missing values and/or questionnaires. 2. Nominal P-value for paired t-test (baseline -endpoint) = 0. 3. Nominal P-value for mean treatment differences between changes from baseline by analysis of covariance with baseline score as covariate. Treatment effects for the corresponding linear mixed model analyses (Weeks 6, 12, 20, and 24 assessments) adjusted for baseline (Week -1) were significant at P < 0.0001 for all scales. For the 12 baseline to endpoint treatment satisfaction difference scores with mean correlation coefficient r = 0.59, compare nominal P-values to a reduced Bonferroni-corrected alpha of 0.018/0.0036/0.0003 to achieve significance at alpha < 0.05/0.01/0.001. 
